<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030676</url>
  </required_header>
  <id_info>
    <org_study_id>18CH053</org_study_id>
    <secondary_id>2018-A01622-53</secondary_id>
    <nct_id>NCT04030676</nct_id>
  </id_info>
  <brief_title>QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis</brief_title>
  <acronym>RECOHFERRON</acronym>
  <official_title>Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more
      severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV)
      reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic
      Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and
      costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against
      CytoMegaloVirus (CMV) in a blood specimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aim to evaluate the performances of this new assay to predict the risk of
      CytoMegaloVirus (CMV) reactivation in the colon of UC patients. A new algorithm for the care
      of Ulcerative Colitis (UC) patients that could be used in all centers, even those without
      molecular biology lab, could be proposed: in case of a positive QuantiFERON-CytoMegaloVirus
      (QF-CMV) assay, the immune response protects the patient against Cytomegalovirus (CMV)
      reactivation and intensification of immunosuppressive therapies should be proposed; at the
      opposite, a negative QuantiFERON-CytoMegaloVirus (QF-CMV) assay will invite to biopsy in
      order to detect CytoMegaloVirus (CMV) replication and to treat with ganciclovir when
      appropriate. This algorithm will preserve invasive biopsies in absence of CytoMegaloVirus
      (CMV) tissue reactivation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load (quantitative PolymeraseChainReaction (qPCR) analysis) in the inflammatory tissue - UI/100 000 cells</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Theses two primary outcomes will determinate the sensibility, specificity, positive predictive value and negative predictive value of the QF-CMV in prediction CMV reactivation in Ulcerative Colitis (UC) patients with acute flare-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QuantiFERON-CytoMegaloVirus (QF-CMV) test result (UI/ml) in blood</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Theses two primary outcomes will determinate the sensibility, specificity, positive predictive value and negative predictive value of the QF-CMV in prediction CMV reactivation in Ulcerative Colitis (UC) patients with acute flare-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of cells infected by CMV (/mm2) by ImmunoHistoChemistry (IHC) in the inflammatory tissue</measure>
    <time_frame>At the inclusion</time_frame>
    <description>To determine the performance threshold of the QuantiFERON-CytoMegaloVirus (QF-CMV) assay as assessed by ImmunoHistoChemistry (IHC) that can predict CytoMegaloVirus (CMV) reactivation in colonic biopsies in Ulcerative Colitis (UC) patients with acute flare-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of the results between quantitative PolymeraseChainReaction (qPCR) and ImmunoHistoChemistry (IHC)</measure>
    <time_frame>At the inclusion</time_frame>
    <description>To evaluate the concordance of the results between quantitative PolymeraseChainReaction (qPCR) and ImmunoHistoChemistry (IHC) analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QuantiFERON-CytoMegaloVirus (QF-CMV) test result (UI/ml) in blood</measure>
    <time_frame>At 14 weeks</time_frame>
    <description>To compare measure of the QuantiFERON-CytoMegaloVirus (QF-CMV) assay at the flare-up and 14 weeks after.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>QuantiFERON Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>Two more biopsies in inflammatory zone will be collected.</description>
    <arm_group_label>QuantiFERON Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.</description>
    <arm_group_label>QuantiFERON Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)

          -  Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score
             &gt; 5 and an endoscopic subscore ≥ 2,

          -  Social security affiliation

          -  Signed informed consent

        Exclusion Criteria:

          -  Wardship patient and curatorial patient

          -  Patient unable to understand or sign the protocol

          -  Patient receiving anticoagulant

          -  Colectomy total or partial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier ROBLIN, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvie PILLET, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier ROBLIN, MD PhD</last_name>
    <phone>(0)477828119</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.roblin@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>Arnauld.Garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier ROBLIN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline VEYRARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie DEL TEDESCO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune response against</keyword>
  <keyword>QuantiFERON-CytoMegaloVirus (QF-CMV)</keyword>
  <keyword>Ulcerative Colitis (UC)</keyword>
  <keyword>CytoMegaloVirus (CMV)</keyword>
  <keyword>quantitative PolymeraseChainReaction (qPCR)</keyword>
  <keyword>ImmunoHistoChemistry (IHC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

